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Introduction
The complement system is a part of the innate immune
system and has several functions, such as clearance of
immune complexes, opsonisation of pathogens, and direct
lysis of invading pathogens by formation of the membrane
attack complex [1]. During complement activation there is a
generation of the biological peptides, C3a and C5a, referred
to as anaphylatoxins. C3a is a chemotactic factor for human
mast cells and eosinophils, and it induces the release of hist-
amine and other vasoactive mediators. C5a has been found
to have a wider range and higher grade of biological activity.
C5a has a chemotactic effect on granulocytes, monocytes,
and macrophages, all of which have receptors for C5a
(CD88). In neutrophil granulocytes, C5a has also been
shown to promote generation of superoxide anions and
release of granule enzymes [2]. Furthermore, C5a has been
shown to induce upregulation of adhesion molecules on neu-
trophils, and is thus also one of the factors responsible for
neutrophil adhesion to endothelial cells [3].
APACHE II = Acute Physiology and Chronic Health Evaluation II; CRP = C-reactive protein; FiO2 = fraction of oxygen in inspired air; FITC = fluores-
cein isothiocyanate; ICU = intensive care unit; mAb = monoclonal antibody; PaCO2 = arterial partial pressure of carbon dioxide; PaO2 = arterial
partial pressure of oxygen; PBS = phosphate-buffered saline.
Abstract
Introduction Treatment of patients with severe sepsis with agents antagonising the effects of C5a has
been proposed based on beneficial effects in animal experiments and in vitro studies demonstrating
upregulation of the C5a receptor (CD88) on granulocytes by endotoxin.
Materials and methods CD88 expression on leukocytes from 12 patients with severe sepsis or septic
shock was analysed by flow cytometer, and serum complement factors C3a and C5b-9 were
measured by enzyme immunoassay techniques.
Results The granulocyte CD88 expression on day 1 was lowered (36; range, 2–59) in comparison
with controls (63; range, 25–88) (P < 0.001), despite complement activation, while the monocyte
CD88 expression was unchanged. The receptor reduction correlated significantly to the APACHE II
score (r2 = 0.35, P < 0.05). The recovery of CD88 expression was slow.
Discussion In contrast to the findings in animals, it is concluded that granulocyte CD88 expression is
reduced at the time when the diagnosis of severe sepsis or septic shock can clinically be made. The
reason for this needs further investigation but it may be due to a previous complement activation or to
cytokine effects.
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To prevent complement-induced destruction of the autolo-
gous cells, the complement system is under strict control
[4,5]. The autologous cell surfaces are protected from homol-
ogous complement by soluble and membrane-bound regula-
tors [6]. Despite this protection, excessive or inappropriate
complement activation has been associated with inflamma-
tory responses in immune complex-dependent diseases and
in adult respiratory distress syndrome [7,8]. Also, in patients
with severe sepsis and septic shock, there is a marked activa-
tion of the complement system [9,10]. In all these conditions,
C5a has been shown to be a mediator of pathophysiological
significance [7,8,10] that has stimulated the development of
specific anti-C5a strategies.
Recent studies in rats have demonstrated that anti-C5a treat-
ment reduces both the mortality and the biological effects
induced by endotoxin [11,12] or polymicrobial products in
the caecal ligation puncture model [13]. Increased expres-
sion of the C5a receptor on the granulocyte has been pro-
posed to be a component of the central mechanism, since it
has been shown that endotoxin can upregulate the C5a
receptor expression in vitro [14,15].
In human infection, CD88 expression of the granulocytes has
only been investigated in HIV infection; and it was then found
to be reduced in advanced disease [16]. To investigate
whether this was also the case in human sepsis or whether
there was an increase in C5a receptor expression similar to
that found in the preclinical experiments, the C5a receptor
expression on granulocytes and monocytes was prospec-
tively studied in patients with severe sepsis or septic shock.
The present results demonstrate that the granulocyte CD88
expression was reduced, suggesting more complicated patho-
genetic mechanisms than those found in animal experiments.
Materials and methods
Patients and controls
Patients who fulfilled clinical criteria supporting a presumptive
diagnosis of severe sepsis or septic shock were prospectively
enrolled in the study. The criteria for severe sepsis and septic
shock were a modification of those defined by Bone et al. [17].
The patients had to fulfil all of the following four criteria. The
acute disease was supposed to be caused by an infection
(positive blood culture not required). Second, there had to be
the presence of a systemic inflammatory response syndrome
defined as two or more of the following criteria: temperature
≤35.6°C or ≥38.3°C; heart rate, ≥90 beats in the absence of
a pacemaker; respiratory rate, ≥20 breaths/min or PaCO2
≤4.3 kPa (32 mmHg); and white blood cell count,
≥1 2×1 0 9/l, ≤4×1 0 9/l, or >10% immature band forms.
The third criterion was the presence of one of the following
parameters indicating organ dysfunction: acute alteration of
mental status, defined as Glasgow Coma Scale <15, not
confounded by sedative, hypnotic or other agents with central
nervous system depressive effects; metabolic acidosis with
pH <7.30 or base deficit ≥5 mEq/l; hypoxia, in the absence
of a pneumonia, defined as PaO2 <9.3 kPa (70 mmHg) on air
ventilation, acute reduction of PaO2 >2 kPa (15 mmHg) on
air ventilation, PaO2/FiO2 <37.3 kPa (280 mmHg), or hypoxia
requiring mechanical ventilation; coagulation abnormalities,
defined as platelet count <100 × 109/l or <50% of a value
measured within the previous 24 hours, an increase in Inter-
national Normalised Ratio or partial thromboplastin time
>50% above the normal value, or D-dimer concentration
>0.5 mg/l; oliguria with urine output <30 ml/hour or <0.5
ml/kg/hour for ≥1 hour; and hypotension defined as persis-
tent systolic blood pressure ≤90 mmHg or reduction
>40 mmHg from a value measured within the previous
24 hours despite adequate fluid resuscitation.
Finally, an informed consent was necessary, or a presumed
consent if the patient was not capable of making decisions
because of altered mental health or sedation.
The exclusion criteria were age <18 years, rapidly progress-
ing underlying disease, HIV/AIDS, cardiogenic shock as the
primary underlying disease, haematologic underlying disease
or cytotoxic therapy given within the previous week expecting
neutropaenia.
The APACHE II score was calculated at the time of the first
blood sampling and retrospectively at the onset of severe
sepsis [18]. In patients sedated because of mechanical venti-
lation or for other reasons, the Glasgow coma score was
recorded as normal [19].
To be able to perform the receptor and functional analyses,
all blood samples were drawn in the morning. Samples were
obtained on three occasions: on the day of inclusion (day 1),
on either of days 2, 3 or 4, and on day 15. EDTA plasma
samples for complement analyses were drawn on day 1.
The second sample was obtained on day 2 in five patients, on
day 3 in five patients, and on day 4 in two patients. Since
there were no statistical differences between these days, the
results from these days are subsequently referred to as day 3.
Twenty healthy individuals with a median age of 46 years
(range, 22–60 years) served as controls.
The study was performed with permission from the Ethics
Committee, Faculty of Medicine, Uppsala University.
Methods
Preparation of leukocytes
Venous blood for receptor analyses on granulocytes and
monocytes was collected in heparinised tubes (Venoject,
Terumo Corporation, Belgium) and processed within 2 hours.
Leukocytes were prepared according to a previouslydescribed method [20]. Briefly, 1 ml blood was mixed with
1 ml of 0.4% (w/v) paraformaldehyde in PBS and warmed to
37°C to fix the blood cells. The mixture was incubated for
4 min at 37°C. The blood sample was then incubated with
40 ml of 0.83% (w/v) NH4Cl in 0.01 M Tris–HCl buffer
(0.01 mol/l Tris[hydroxymethyl]–aminomethane, pH 7.4) for
15 min at 37°C to lyse the red blood cells. The cells were
then centrifuged for 5 min at 350 × g at room temperature,
and the supernatant and the red blood cell debris were
removed. The remaining leukocytes were washed twice with
PBS/citrate/human serum albumin. The cells were then
diluted with PBS/citrate/human serum albumin and counted.
The concentration of the granulocytes was adjusted to
(1.7–2.5) × 106/ml.
Labelling of leukocytes with antibodies to cell surface antigens
To each tube were added 50 µl cell suspension, optimally
titrated FITC-labelled anti-CD88, clone W17/1 (Serotec,
Raleigh, NC, USA) or FITC-labelled isotype control antibod-
ies (Dakopatts A/S, Glostrup, Denmark), and phycoerythrin-
labelled anti-CD14 (Dakopatts). This CD88 antibody has
been demonstrated to bind to the same part of the receptor
as C5a [21]. The samples were then incubated on ice for
30 min. After that, the cells were washed twice with ice-cold
PBS/citrate. The cells were diluted with 200 µl PBS/citrate/
human serum albumin and then kept on ice until analysis.
Flow cytometry
The samples were analysed on an EPICS-PROFILE II flow
cytometer (Coulter Company Inc, Hialeah, FL, USA). The
analysis used a fixed protocol, with the same settings main-
tained for forward scatter and side scatter throughout the
study. The fluorescence was calibrated daily, to compensate
for the variation of the signals from the flow cytometer, using
standardised beads (Flow Set; Coulter Company Inc).
The granulocytes and monocytes were separated on the basis
of their forward scatter and side scatter patterns, and the
staining with anti-CD14 was used to check the identification
of the monocytes. Gates were set around the granulocyte and
monocyte populations, and the FITC fluorescence within the
gates was measured. A minimum of 10,000 events in the
granulocyte gate was counted. The granulocyte and monocyte
expression of the C5a receptor (CD88) was measured as
specific mean fluorescence intensity of the whole population
of granulocytes and monocytes, and as the relative amount of
CD88-positive granulocytes and monocytes. The specific
mean fluorescence intensity of the granulocyte and monocyte
C5a receptor expression was calculated by subtracting the
background mean fluorescence intensity obtained with the
negative isotype control mAb from the value obtained with the
anti-CD88 mAb. The relative amounts of C5a receptor-posi-
tive granulocytes or monocytes were calculated as the relative
numbers of granulocytes or monocytes, respectively, showing
a higher fluorescence intensity when stained with the anti-
CD88 mAb than with the negative control mAb.
The interassay variation was 25%, while the intra-assay
variation was 7%. A patient sample was always analysed
concomitantly with a sample obtained from a healthy control.
Analyses of complement components
The blood for complement analyses was collected in EDTA
tubes (Becton Dickinson, Plymouth, UK) and kept on ice until
centrifugation. The plasma was collected and stored at –70°C.
The concentration of C3a was analysed by an enzyme
immunoassay that is a sandwich enzyme immunoassay
employing the monoclonal antibody 4SD17.3 as the capture
antibody. EDTA plasma was diluted 1/500 and analysed as
described previously [22]. Bound C3a was detected with
biotinylated rabbit anti-C3a followed by horseradish peroxi-
dase-conjugated streptavidin (Amersham, Amersham, UK).
Zymosan-activated serum [23], calibrated against a solution
of purified C3a [24], served as standard and the values are
given in nanograms per millilitre.
Soluble C5b-9 was analysed by a modified enzyme
immunoassay, described by Mollnes et al. [25]. Plasma
samples, diluted 1/5, were added to microtitre plates coated
with anti-neoC9 mAb MCaE11. Soluble C5b-9 was detected
by polyclonal anti-C5 antibodies diluted 1/500, followed by
horseradish peroxidase-conjugated antirabbit immunoglobulin
diluted 1/500 (both from Dako A/S, Denmark). Zymosan-
activated serum defined as containing 40,000 arbitrary units
per millilitre served as the standard. The interassay variation
of the C3a and the C5b-9 analyses was 10%.
Leukocyte count
Leukocyte counts were made on a Coulter STKS (Beckman
Coulter Inc, Hialeah, FL, USA).
Statistics
Statistical analysis was performed in a nonparametric manner
using the Mann–Whitney U test for comparison of data
between patients and controls and between patient groups.
One healthy control was used at each analysis and a total of
20 control patients were employed. Some controls were
therefore analysed on two or three occasions. For the
Mann–Whitney analysis, only the value obtained at the first
analysis was used in the calculations.
The Wilcoxon matched-pairs test was employed for compari-
son of individual data within the patient group. The Spearman
rank-order correlation coefficient was calculated for correla-
tion analyses.
A difference between two groups was considered significant
when  P < 0.05. The software STATISTICA (StatSoft Inc.,
Tulsa, OK, USA) was used in the statistical calculations.
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Twelve patients (seven males and five females), with a
median age of 58 years (range, 21–85 years), admitted to the
intensive care unit (ICU) fulfilled the criteria and were entered
into the study. Patient characteristics are presented in
Table 1. Three patients were admitted to the ICU with a
severe infection as the principal cause. Six patients had prob-
able postoperative infections, one patient had a postburn
infection, one patient had a pancreatic abscess, and one
patient developed pneumonia after having been admitted to
the ICU because of severe hypercalcaemia and malnutrition.
Infection was verified in all but one patient. In three patients
treated with broadspectrum antibiotics for several days
before sampling, cultures were negative or they demon-
strated bacteria or fungi that were interpreted as colonisation.
Causes of the deterioration other than infection could be
ruled out in these patients. Although an infection cannot be
excluded in patient 11, a retroperitoneal haematoma might
have explained the postoperative deterioration at the time of
enrolment. Culture findings are presented in Table 1.
Because patient 11 fulfilled the prospectively designed inclu-
sion criteria for severe sepsis and would have been enrolled
in a clinical trial using these criteria, this patient was included
in the further analyses. Patient 3 died in septic shock after 5
days, and patient 6 died after 28 days. Patient 10 was
referred to another hospital on day 5. The ICU mortality, the
28-day mortality, and the hospital mortality were 8, 17, and
33%, respectively. The median length of the ICU stay was
15 days.
The first blood samples were obtained within 24 hours in
eight patients after having fulfilled the criteria for severe
sepsis, and in another four patients within 36 hours. The
median APACHE II score at onset of severe sepsis was 17
(range, 12–28). At the time of the first blood sampling, the
APACHE II score had improved in three patients, had wors-
ened in four patients, and was more or less unchanged in the
other patients, the median APACHE II score still being 17
(range, 13–26). All patients were febrile at this time and
demonstrated serum C-reactive protein (CRP) concentration
>100 mg/l, which was on the rise in all but three patients.
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Table 1
Patient characteristics
Sex, age  APACHE II score,  Day 28 
Patient (years) Underlying disease Diagnosis of infection Significant culture findings debut/inclusion mortality
1 Male, 56 Renal transplantation Streptococcal sepsis β-Haemolysing streptococci  27/26 Alive
group A in wound culture
2 Female, 85 Hypertension Bilateral pneumonia No positive cultures 21/20 Alive
3 Female, 53 Arteriosclerosis,  Postoperative sepsis Coagulase-negative staphylococci  15/16 Dead
infected aortic graft in graft culture
4 Male, 81 Cholelithiasis Klebsiella sepsis,  Klebsiella pneumophila in blood culture 22/16 Alive
cholecystitis
5 Male, 21 Pancreatitis Pancreatic abscess No positive cultures 12/13 Alive
6 Male, 74 Aortic aneurysm Postoperative  Proteus mirabilis, Citrobacter freudi, 20/18 Dead
abdominal infection Candida albicans and Candida glabrata
in abdominal fluid and wound cultures
7 Male, 55 Stroke, alcohol abuse,  Burn wound infection Enterobacter cloacae and Klebsiella  16/18 Alive
angina pectoris pneumophila in wound cultures
8 Male, 61 Alcohol abuse,  Pneumonia No positive cultures 18/11 Alive
malignancy, hypercalcemia
9 Female, 78 Angina pectoris,  Postoperative sepsis Candida albicans in tracheal culture 15/22 Alive
necrotising pancreatitis
10 Female, 51 Diabetes, arteriosclerosis,  Necrotising infection of  Enterococcus faecalis in blood culture 28/18 Alive
myocardial infarctions,  the calf muscles
infarction in cerebellum, 
embolus in arteria poplitea 
and compartment syndrome
11 Male, 74 Sigmoideum cancer Postoperative  No positive cultures 13/13 Alive
abdominal infection?
12 Female, 73 Idiopathic thrombocyto- Postoperative sepsis Staphylococcus aureus in wound  12/14 Alive
paenia, arteriosclerosis,  culture
aortic graftThe median CD88 expression on the granulocytes in the
healthy control group was 63 (range, 25–88). At the time of
first sampling on day 1, the granulocyte CD88 expression in
the patients with severe sepsis was significantly lower at 36
(range, 2–59; P < 0.001) (Fig. 1).
In comparison with the value obtained from the healthy indi-
viduals analysed on the same occasion, CD88 expression
was lower in all patients except patient 11. There was some
increase in CD88 expression on day 3 (37; range, 6–101),
and the increase was significant after 2 weeks in comparison
with day 1 (51; range, 20–105) (P < 0.05). Both on day 3
and on day 15, however, the granulocyte CD88 expression
was still significantly reduced in comparison with that of the
healthy controls (P < 0.05). The recovery followed an individ-
ual course, since granulocyte CD88 values on day 15 were
highly correlated with those on day 1 (r2 = 0.64, P < 0.01).
The median granulocyte CD88 expression in patients who
remained in the ICU on day 15 had been 35 (range, 2.5–59)
on day 1, compared with 44 (range, 26–57) on day 1 in
those who were discharged from the ICU on day 15
(P < 0.05). Granulocyte CD88 expression on day 1 was 18.9
in the patient who died in the ICU on day 5. This expression
was further reduced to 12.6 on the day before death.
Monocyte CD88 expression was considerably lower than gran-
ulocyte CD88 expression, both in healthy controls (P < 0.01)
and in the patients (P < 0.05). In contrast to the granulocyte
CD88 expression, the monocyte CD88 expression was totally
unchanged over the time of observation and there was no dif-
ference between patients and the controls (Fig. 1).
The leukocyte counts on the different days are presented in
Table 2. There was no correlation between granulocyte count
and CD88 expression on day 1 (r2 = 0.05) or on day 3
(r2 = 0.03), indicating that the reduction in C5a receptor
expression during acute infection cannot be explained by a vari-
ation in the number of leukocytes. On day 15, however, there
was a small but significant negative correlation with lower
values in patients with leukocytosis (r2 = 0.24; P < 0.05).
The granulocyte expression of CD88 on day 1 correlated
negatively to the severity of disease as measured by the
APACHE II score at inclusion (r2 = 0.35, P < 0.05) (Fig. 2).
This correlation was influenced neither by the changes in
APACHE II score from the onset of severe sepsis nor by the
duration of severe sepsis. Overall, there was no significant
correlation either to the varying duration of the severe sepsis
at inclusion or to the duration of acute illness. There was no
correlation between APACHE II score and monocyte CD88
expression (r2 = 0.00).
Granulocyte CD88 expression on day 1 did not correlate to
the inflammatory process as indicated by the level of serum
CRP. Later during the clinical course, however, these para-
meters correlated significantly (r2 = 0.42, P < 0.05 on day 2;
r2 = 0.50, P < 0.05 on day 15). There was no significant cor-
relation between the monocyte CD88 expression and the
concentration of serum CRP on any of the days.
C5b-9 levels were increased in all patients and C3a concen-
trations were increased in all but one patient on day 1
(Table 3). There was no correlation between C5b-9 or C3a
levels and neutrophil or monocyte CD88 expression.
Discussion
To avoid clinical trials with little chance of proving efficacy of
different anti-C5a strategies, it was of interest to study
whether the increased expression of the C5a receptor found
in the animal experiments was found also in human sepsis.
Theoretically, it would also have been of interest to study the
C5a concentration. However, C5a concentration is not a
good parameter to follow complement activation.
C5a binds rapidly to the C5a receptor and, in contrast to C3a,
C5a is cleared from plasma within minutes [26,27]. In a clini-
Available online http://ccforum.com/content/6/4/363
Figure 1
Granulocyte and monocyte expression of CD88 in patients with severe
sepsis on day 1, day 3, and day 15. Values are expressed as the
median, and the 25th and 75th percentiles. * P < 0.05, *** P < 0.001
in the comparison with the healthy controls (Mann–Whitney U test).











Day 1 Day 15 Day 3
Table 2
Leukocyte cell count on day 1, on day 3 and on day 15
Day 1 Day 3 Day 15
Total leukocyte cell  16.2  18.3  11.2 
count (× 109/l) (8.1–34.6) (6.3–34.6) (7.2–18.9)
Polynuclear cells  13.6  15.6  8.0 
(× 109/l) (5.8–33.5) (3.7–31.4) (4.0–16.6)
Mononuclear cells  1.7  2.1  2.2 
(× 109/l) (0.7–15.5) (0.5–6.0) (1.4–5.5)
Data presented as median (range).cal trial including patients with sepsis and complement activa-
tion, as assessed by increased C3a concentrations and
C3a/C3 ratios, the C5a values found were identical to those
in healthy controls [10]. Besides being an important parameter
of complement activation of its own, the concentration of C5b-
9 analysed in this study is an indirect measurement of the C5a
production, since C5 at activation is split into C5a and C5b.
In this study patients with severe sepsis or septic shock, the
increased levels of C3a and C5b-C9 indicate complement
activation in agreement with the animal experiments and a
previous clinical study [10]. In contrast to the findings in the
animal experiments [14,15], however, CD88 expression on
the granulocytes was markedly reduced. In the acute phase,
this was probably not a compensatory effect due to the leuko-
cytosis because the correlation between granulocyte count
and expression of CD88 was slightly positive on day 1. There
was a slow recovery and, after 2 weeks, the granulocyte
CD88 expression was still lower than in healthy controls.
Although there are signs of complement activation, the
present results demonstrate that granulocyte CD88 expres-
sion is reduced at the time when the diagnosis of severe
sepsis or septic shock can clinically be made. Since the
analyses of the CD88 expression had to be performed within
2 hours after blood sampling, because of the changes in cell
surface receptor expression during longer storage periods, all
the analyses had to be performed during daytime working
hours. There was therefore a delay after the onset of severe
sepsis or septic shock. However, as can be seen in Fig. 2,
the duration of the severe sepsis did not seem to affect the
results. Statistically, there was no correlation between dura-
tion of sepsis and the granulocyte CD88 expression.
It may also be speculated that deteriorating patients, being in
a more uncontrolled phase, perhaps would have higher
values than patients demonstrating signs of improvement.
The present data do not suggest that this factor was of great
importance (Fig. 2). Although a minor effect of these factors
cannot be excluded, it must be emphasised that the CD88
expression was lower in all patients but one than in the con-
comitantly analysed healthy controls, irrespective of the dura-
tion of sepsis or whether the sepsis was improving.
Furthermore, the patient in whom the granulocyte CD88
expression was within the range of the controls was the one
in whom infection could not be verified.
Moreover, it may be argued that the patients included in this
study were not ill enough. However, the reduction in granulo-
cyte CD88 expression was more pronounced in the more
severe cases, as indicated by the negative correlation to the
APACHE II score and by the fact that patients who were not
discharged from the ICU 2 weeks later had shown lower
values on day 1.
In the animal experiments in which anti-C5a strategies were
beneficial, the treatment was given concomitantly or before
the endotoxin injection [11,12] or the establishment of the
infection [13]. In humans, a transient increase in C5a binding
to granulocytes has been demonstrated 3 hours after low-
dose endotoxin administration [14]. After that there was a
successive decrease, and after 24 hours the mean value was
below that at baseline.
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Figure 2
Correlation between the granulocyte CD88 expression and the
APACHE II score on day 1. Upward arrows indicate an increase from
onset of the severe sepsis in APACHE II score >2, and downward
arrows indicate a decrease from onset of the severe sepsis in
APACHE II score >2. Double-directed arrows represent changes <2.
 , a patient with a duration of sepsis of 12 hours;  , a patient with a
duration of 13–24 hours; and  , a patient with a duration >24 hours.
Patients who died within 28 days are marked with shaded symbols. A
regression line has been calculated using the method of least squares.














Concentrations of C3a and C5b-9 on day 1
Number of patients with values 
above upper normal limit Median Range Normal range
C3a 10/11 1106 ng/ml 259–1529 ng/ml 92–268 ng/ml
C5b-9 11/11 147 AU/ml 64–562 AU/ml 12–56 AU/ml
AU, arbitrary unitsIt has been shown in in vitro experiments that, after binding of
C5a, the receptor complex is rapidly internalised, thus render-
ing the cells resistant to subsequent challenges with C5a
[28]. Thus, it cannot be excluded that, in our patients with
sepsis and signs of complement activation, there might have
been an initial transient upregulation of the granulocyte C5a
receptor. At the time of diagnosis, however, this expression
has become reduced, possibly as a consequence of a previ-
ous stimulation. If this is the scenario, it might be hypothe-
sised that anti-C5a treatment may be effective if given before
or concomitantly with infectious stimuli, but without effect if
given later in the septic course. To our knowledge, there are
so far no results published from animal experiments in which
the anti-C5a treatment has been postponed until signs of
severe sepsis have become evident.
Another reason for the discrepancy may be that endotoxin or
polymicrobial sepsis by the caecal ligation puncture model
caused the septic reaction in the experimental models, while
infections in our heterogeneous patient group with clinical
sepsis were caused both by Gram-positive and Gram-nega-
tive bacteria. However, our limited data do not indicate a dif-
ference between Gram-positive and Gram-negative
infections. To our knowledge, there are no animal experi-
ments investigating the C5a receptor or anti-C5a treatment in
Gram-positive infections.
It must also be emphasised that a low granulocyte C5a
receptor expression does not theoretically exclude an
ongoing granulocyte activation by C5a. One possibility would
be that the reduced receptor level detected by the CD88
antibody may be caused by receptor-bound C5a, and another
that the receptor of the internalised complex is rapidly trans-
ported back to the cell surface to bind more C5a. Studies in
humans and animals, however, have all shown a rapid inter-
nalisation of the ligand–receptor complex after binding, and
thereafter there is a desensitisation to subsequent challenges
with C5a [13,29]. There are no data indicating an increase in
recycling of the receptor in sepsis or in any other condition.
Other reasons for the reduction in granulocyte C5a receptor
expression may be the inflammatory response or the infection
per se. The correlation to the CRP response might suggest
that there is a relation to the inflammatory response. This is
best studied in in vitro experiments and in a new prospective
clinical investigation in which there is parallel inclusion of sys-
temic inflammatory response syndrome patients with and
without infection. Another theoretical possibility might be that
immature granulocytes recently released from the bone
marrow may have a lower CD88 expression. With the rapid
turnover that occurs during severe sepsis and septic shock,
such cells would account for a substantial part of the granulo-
cyte cell population. There are presently no data to support a
lower CD88 expression on younger cells, but the negative
correlation between granulocyte count and CD88 expression
on day 15 may be consistent with such a mechanism.
In contrast to the changes in the granulocyte CD88 expres-
sion, there were no changes in the monocyte expression. The
reason for this discrepancy is not known but may be caused
by the differential effects of proinflammatory or anti-inflamma-
tory substances on granulocytes and monocytes, by differ-
ences in the affinity to C5a, or by a bone marrow effect in
combination with varying half-lives.
Conclusion
A reduction in granulocyte C5a receptor expression has been
demonstrated in patients at the time when the diagnosis of
severe sepsis or septic shock can be clinically established.
The number of patients in the present study is limited.
However, the strongly significant reduction in granulocyte
CD88 expression and its correlation with disease severity in
included patients clearly indicate that severe sepsis in clinical
practice reflects other mechanisms than those seen in the
animal experiments and that inclusion of further patients
would not reasonably have led to an alternative conclusion.
The reduction in granulocyte C5a expression may perhaps
implicate a risk that the clinical response to anti-C5a treat-
ment might be more limited than that seen in animal experi-
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